| New from NCI |
| Supporting Research to End Cancer as We Know It |
 |
|
NCI’s support of cancer research is helping reduce the burden of cancer by improving cancer risk assessment, prevention, detection, diagnosis, treatment, and survivorship. In this section of the NCI Fiscal Year 2026 Annual Plan and Professional Judgment Budget Proposal, learn more about the cancer research continuum and how sustained support for NCI’s work is needed to end cancer as we know it for all.
Read More
|
| Tool Improves Supportive Care in Young People with Cancer |
 |
|
Results from two clinical trials have shown that younger people with cancer who filled out surveys about their symptoms ended up having fewer cancer-related symptoms than those who did not complete the surveys. The findings show that patient-reported outcome (PRO) surveys for children can give an accurate picture of how a child is feeling during the stress of treatment.
Read More
|
| Advances in Pancreatic Research |
 |
|
Find out what’s new in pancreatic cancer research on this updated page. Topics include current progress in treatment with stroma-modifying drugs and immunotherapy. It also describes selected NCI-supported programs that address pancreatic cancer.
Read More
|
Engineered E. coli Shrink Tumors in Mice
Two research teams engineered a probiotic strain of E. coli called Nissle 1917 so it can help the immune system attack tumors. Although the E. coli were altered in different ways, resulting in two different immune-based treatment strategies, both were effective in mice.
Read More
|
Treatment May Target Tumors Driven by Free-Floating DNA
Researchers have found that cancer cells containing extrachromosomal DNAs (free-floating chunks of DNA) have a weakness that can be exploited by a drug that targets the CHK1 protein. In mice, combining the drug with another targeted therapy kept cancer at bay for long periods.
Read More
|
PSA Test
This updated page explains the PSA (prostate specific antigen) test and how it is used. Learn about prostate screening guidelines, what happens if a PSA test shows an abnormal result, and how the test is used in people who have been treated for prostate cancer.
Read More
|
Durvalumab for Small Cell Lung Cancer
The Food and Drug Administration expanded the approval of durvalumab (Imfinzi) to include limited-stage small cell lung cancer that didn’t get worse after treatment with platinum-based chemotherapy given at the same time as radiation therapy. Durvalumab was previously approved for use with chemotherapy to treat extensive-stage disease.
Read More
|
